3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Marijuana Abuse
2
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Pancreatic Cancer Non-resectable
1
Pain
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Marijuana Use
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Interventions
Sorafenib
202
lenvatinib
129
Bevacizumab
124
Nivolumab
85
pembrolizumab
72
atezolizumab
72
Radiosurgery
71
durvalumab
63
Oxaliplatin
59
sintilimab
57
Fluorouracil
54
Doxorubicin
44
tislelizumab
43
apatinib
43
Leucovorin
40
tremelimumab
37
camrelizumab
37
Radiofrequency Ablation
37
Radiotherapy
36
Magnetic Resonance Spectroscopy
32
Capecitabine
30
regorafenib
29
Folfox protocol
29
Cisplatin
28
cabozantinib
26
Hepatectomy
26
Gemcitabine
26
Cyclophosphamide
26
Ipilimumab
25
toripalimab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Hepatocellular
×
Medical Marijuana
×
Clear all
NCT06518434
2024-07-24
CanHep
University Medical Center Groningen
Phase 2
Recruiting
20 enrolled